2-(3-bromophenyl)-5-(trifluoromethyl)-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrazol-3-one | 1257411-92-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(3-bromophenyl)-5-(trifluoromethyl)-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrazol-3-one
• CAS: 1257411-92-9
• 化学式: C₂₀H₁₆BrF₃N₂O₄
• 分子量: 485.257
• InChiKey: OEZGDCSNHSYCMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(3-Bromophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-ol 、 3,4,5-三甲氧基苯甲醛 以 水 为溶剂， 生成 2-(3-bromophenyl)-5-(trifluoromethyl)-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrazol-3-one
  参考文献：
  名称：

  Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold

  摘要：

  HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.057

文献信息

• Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold
  作者：Victor Hadi、Yung-Hyo Koh、Tino Wilson Sanchez、Danielle Barrios、Nouri Neamati、Kyung Woon Jung

  DOI：10.1016/j.bmcl.2010.08.057

  日期：2010.11

  HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.